3,3'-Diindolylmethane decreases VCAM-1 expression and alleviates experimental colitis via a BRCA1-dependent...

Area of Science:

• Gastroenterology
• Immunology
• Molecular Biology

Background:

• Reactive oxygen species (ROS) play a critical role in the pathogenesis of inflammatory bowel disease (IBD).
• 3,3'-Diindolylmethane (DIM) has demonstrated protective effects against oxidative stress, potentially via a breast cancer susceptibility gene 1 (BRCA1)-dependent mechanism.

Purpose of the Study:

• To investigate the therapeutic potential of DIM in experimental colitis.
• To elucidate the underlying mechanisms of DIM's effects on intestinal inflammation, focusing on oxidative stress and immune cell adhesion.

Main Methods:

• Experimental colitis was induced using 2,4,6-trinitrobenzene sulfonic acid (TNBS).
• DIM's effects on pathological markers, antioxidant activity, and ROS generation in colonic tissue were assessed.
• DIM's impact on ROS-induced vascular cell adhesion molecule 1 (VCAM-1) expression and leukocyte-endothelial cell interactions was studied in vitro and in vivo.

Main Results:

• DIM administration significantly attenuated TNBS-induced colitis, improving pathological indices.
• DIM treatment stimulated BRCA1 expression both in vitro and in vivo.
• DIM reduced ROS generation, leading to decreased VCAM-1 expression and leukocyte-endothelial cell adhesion, thereby alleviating colitis.

Conclusions:

• DIM exhibits anti-inflammatory bowel disease activity in preclinical models.
• DIM functions through a BRCA1-dependent antioxidant pathway to inhibit ROS-induced VCAM-1 expression and leukocyte recruitment.
• DIM represents a potential therapeutic agent for patients with inflammatory bowel disease.